Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease

Published:2021-02-16 Issue:4 Volume:64 Page:1966-1988
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhang Chufeng¹,Qi Wenyan¹,Li Yong¹,Tang Minghai¹,Yang Tao¹,Liu Kongjun¹,Chen Yong¹,Deng Dexin¹,Xiang Mingli¹,Chen Lijuan¹^ORCID

Affiliation:

1. State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China

Funder

National Natural Science Foundation of China

West China Hospital, Sichuan University

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01468

Reference41 articles.

1. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

2. Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models